The analgesic effect of tramadol in animal models of neuropathic pain and fibromyalgia

Neuroscience Letters

Volumn 562, Issue , 2014, Pages 28-33

  Kaneko, Kumi ^a   Umehara, Masato ^a   Homan, Takashi ^a   Okamoto, Ken ^a   Oka, Michiko ^a   Oyama, Tatsuya ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Fibromyalgia; Naloxone; Neuropathic pain; Opioid; Partial sciatic nerve ligation; Reserpine; Tramadol

Indexed keywords

NALOXONE; OPIATE RECEPTOR; RESERPINE; TRAMADOL;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC PAIN; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROMYALGIA; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SCIATIC NERVE; TACTILE STIMULATION; VON FREY TEST;

FIBROMYALGIA; NALOXONE; NEUROPATHIC PAIN; OPIOID; PARTIAL SCIATIC NERVE LIGATION; RESERPINE; TRAMADOL;

ANALGESICS, OPIOID; ANIMALS; CHRONIC PAIN; DISEASE MODELS, ANIMAL; FIBROMYALGIA; MALE; NEURALGIA; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; TRAMADOL;

EID: 84892999909     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.01.007     Document Type: Article

References (35)

1. Maag R., Baron R. Neuropathic pain: translational research and impact for patient care. Curr. Pain Headache Rep. 2006, 10:191-198.
2. Jaggi A.S., Jain V., Singh N. Animal models of neuropathic pain. Fundam. Clin. Pharmacol. 2011, 25:1-28.
3. Seltzer Z., Dubner R., Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990, 43:205-218.
4. Russell I.J., Vaeroy H., Javors M., Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992, 35:550-556.
5. Sluka K.A., Kalra A., Moore S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001, 24:37-46.
6. Khasar S.G., Green P.G., Levine J.D. Repeated sound stress enhances inflammatory pain in the rat. Pain 2005, 116:79-86.
7. Nishiyori M., Ueda H. Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol. Pain 2008, 4:52.
8. Nagakura Y., Oe T., Aoki T., Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 2009, 146:26-33.
9. Furuta S., Shimizu T., Narita M., Matsumoto K., Kuzumaki N., Horie S., Suzuki T., Narita M. Subdiaphragmatic vagotomy promotes nociceptive sensitivity of deep tissue in rats. Neuroscience 2009, 164:1252-1262.
10. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 2004, 43:879-923.
11. Frink M.C., Hennies H.H., Englberger W., Haurand M., Wilffert B. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 1996, 46:1029-1036.
12. Lai J., Ma S.W., Porreca F., Raffa R.B., Tramadol M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur. J. Pharmacol. 1996, 316:369-372.
13. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J. Pharmacol. Exp. Ther. 1992, 260:275-285.
14. Oliva P., Aurilio C., Massimo F., Grella A., Maione S., Grella E., Scafuro M., Rossi F., Berrino L. The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component. Eur. J. Pharmacol. 2002, 445:179-185.
15. Oyama T., Homan T., Kyotani J., Oka M. Effect of tramadol on pain-related behaviors and bladder overactivity in rodent cystitis models. Eur. J. Pharmacol. 2012, 676:75-80.
16. 2C receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Pharmacol. Biochem. Behav. 2013, 108:8-15.
17. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 1994, 53:55-63.
18. Apaydin S., Uyar M., Karabay N.U., Erhan E., Yegul I., Tuglular I. The antinociceptive effect of tramadol on a model of neuropathic pain in rats. Life Sci. 2000, 66:1627-1637.
19. 1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. Psychopharmacology (Berl) 2007, 193:97-105.
20. Hama A., Sagen J. Altered antinociceptive efficacy of tramadol over time in rats with painful peripheral neuropathy. Eur. J. Pharmacol. 2007, 559:32-37.
21. Kim S.H., Song J., Mun H., Park K.U. Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia. Korean J. Intern. Med. 2009, 24:139-142.
22. Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol. Rep. 2009, 61:978-992.
23. Leppert W., Łuczak J. The role of tramadol in cancer pain treatment--a review. Support Care Cancer 2005, 13:5-17.
24. Boureau F., Legallicier P., Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003, 104:323-331.
25. Harati Y., Gooch C., Swenson M., Edelman S., Greene D., Raskin P., Donofrio P., Cornblath D., Sachdeo R., Siu C.O., Kamin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842-1846.
26. Hollingshead J., Dühmke R.M., Cornblath D.R. Tramadol for neuropathic pain. Cochrane Database Syst. Rev. 2006, CD003726.
27. Russell I.J., Kamin M., Bennett R.M., Schnitzer T.J., Green J.A., Katz W.A. Efficacy of tramadol in treatment of pain in fibromyalgia. J. Clin. Rheumatol. 2000, 6:250-257.
28. Bennett R.M., Kamin M., Karim R., Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am. J. Med. 2003, 114:537-545.
29. Heymann R.E., Helfenstein M., Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin. Exp. Rheumatol. 2001, 19:697-702.
30. Mease P.J., Clauw D.J., Gendreau R.M., Rao S.G., Kranzler J., Chen W., Palmer R.H. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J. Rheumatol. 2009, 36:398-409.
31. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., Walker D.J., Chappell A.S., Arnold L.M. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444.
32. Rao S.G., Clauw D.J. The management of fibromyalgia. Drugs Today (Barc.) 2004, 40:539-554.
33. Brederson J.D., Jarvis M.F., Honore P., Surowy C.S. Fibromyalgia: mechanisms, current treatment and animal models. Curr. Pharm. Biotechnol. 2011, 12:1613-1626.
34. Sörensen J., Bengtsson A., Ahlner J., Henriksson K.G., Ekselius L., Bengtsson M. Fibromyalgia-are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J. Rheumatol. 1997, 24:1615-1621.
35. Harris R.E., Clauw D.J., Scott D.J., McLean S.A., Gracely R.H., Zubieta J.K. Decreased central μ-opioid receptor availability in fibromyalgia. J. Neurosci. 2007, 27:10000-10006.